The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Cardiorenal Safety of OTC Analgesics
Open accessAbstract
Over-the-counter analgesics are used globally for the relief of acute pain. Although effective, these agents can be associated with adverse effects that may limit their use in some people. In the early 2000s, observations from clinical trials of prescription-strength and supratherapeutic doses of nonselective and cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs (NSAIDs) raised safety concerns regarding the risk of cardiovascular adverse effects with the use of these medications. Subsequently, the US Food and Drug Administration mandated additional study of the cardiovascular safety of NSAIDs for a more comprehensive understanding of their risk. As these data were being collected, and based on a comprehensive review of prescription data and the recommendations of the US Food and Drug Administration Advisory Committee, the warning labels of over-the-counter NSAIDs were updated to emphasize the potential cardiovascular risks of these agents. The recently reported “Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen” (PRECISION) trial, in which participants with osteoarthritis or rheumatoid arthritis and underlying cardiovascular risk factors were treated with prescription-strength celecoxib, ibuprofen, or naproxen, revealed similar rates of cardiovascular events (death from cardiovascular causes including hemorrhagic death, nonfatal myocardial infarction, or nonfatal stroke) among the 3 treatment groups. Although informative, the cardiovascular safety findings derived from PRECISION cannot be extrapolated to the safety of the over-the-counter pain relievers ibuprofen and naproxen, given that the doses used were higher (mean [standard deviation]: ibuprofen, 2045 [246] mg; naproxen, 852 [103] mg) and the durations of use longer (∼20 months) than recommended with over-the-counter use of NSAIDs, which for ibuprofen is up to 10 days. This review discusses the cardiorenal safety of the most commonly used over-the-counter analgesics, ibuprofen, naproxen, and acetaminophen. Available data suggest that there is little cardiovascular risk when over-the-counter formulations of these agents are used as directed in their labels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“No robust evidence supports an association between paracetamol and adverse cardiovascular outcomes (stroke or myocardial infarction) in patients with atherosclerotic heart diseases.94–96”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006) · BMJ · doi:10.1136/bmj.332.7553.1302 · Cited by 1,445 · cited 10×
“Participants were divided into 4 groups: (1) ASA alone, (2) ASA plus ibuprofen, (3) ASA plus diclofenac, and (4) ASA plus any other NSAIDs.”
BackgroundInfluentialCyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003199 · Cited by 1,394
McGettigan, P., & Henry, D. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60011 · Cited by 1,096
Harirforoosh, S., Asghar, W., & Jamali, F. (2014) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vw2f · Cited by 960 · cited 1×
“Confounding factors during NSAID use include the fact that inflammatory conditions are associated with CV complications and that some CV medications may have less efficacy or altered pharmacokinetics in inflammatory states.(54,55) Pathophysiologic Effects of NSAIDs on BP Prostaglandin E2 decreases renal Na þ reabsorpt…”
BackgroundHarris, R. C., McKanna, J. A., Akai, Y., Jacobson, H. R., Dubois, R. N., & Breyer, M. D. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117620 · Cited by 860 · cited 1×
“Cyclooxygenase 2 is an inducible enzyme expressed in the brain, kidney, and possibly in the female reproductive system.(37,42,43) Cyclooxygenase 2 expression is increased during states of inflammation.”
BackgroundCardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis
Nissen, S. E., Yeomans, N. D., Solomon, D. H., Lüscher, T. F., Libby, P., Husni, M. E., Graham, D. Y., Borer, J. S., Wisniewski, L. M., Wolski, K. E., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611593 · Cited by 856
Graham, G. G., Davies, M. J., Day, R. O., Mohamudally, A., & Scott, K. F. (2013) · Inflammopharmacology · doi:10.1007/s10787-013-0172-x · Cited by 671
Research works printed but not linked: 3
- Hirst JJ, 1995, J Clin Endocrinol Metab, 80, 517
- Fanelli A, 2013, Acta Biomed, 84, 5
- Epstein M, 2002, J Hypertens Suppl, 20, S17
Cited by
Urban, P., Mehran, R., Colleran, R., Angiolillo, D. J., Byrne, R. A., Capodanno, D., Cuisset, T., Cutlip, D., Eerdmans, P., Eikelboom, J., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.040167 · Cited by 823
Self-citationUrban, P., Mehran, R., Colleran, R., Angiolillo, D. J., Byrne, R. A., Capodanno, D., Cuisset, T., Cutlip, D., Eerdmans, P., Eikelboom, J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz372 · Cited by 621
“NSAIDs represent the most widely used class of medications worldwide.(124,125) Both oral NSAIDs and steroids are associated with increased gastrointestinal bleeding risk, which is dose-dependent and increases with long-term use.”
BackgroundSelf-citationMallet, C., Desmeules, J., Pegahi, R., & Eschalier, A. (2023) · Journal of Pain Research · doi:10.2147/jpr.s393809 · Cited by 83
Alchin, J., Dhar, A., Siddiqui, K., & Christo, P. J. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2049551 · Cited by 65
Accelerated Atherosclerosis in Rheumatoid Arthritis: Mechanisms and Treatment
Reiss, A. B., Silverman, A., Khalfan, M., Vernice, N. A., Kasselman, L. J., Carsons, S. E., & Leon, J. D. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190430113212 · Cited by 42
Metadata
- Authors
- White, W. B., Kloner, R. A., Angiolillo, D. J., & Davidson, M. H.
- Affiliations
- University of Connecticut (US)
- University of Southern California (US)
- University of Florida (US)
- University of Chicago (US)
- Corresponding author
- White, William B.
- Venue
- Journal of Cardiovascular Pharmacology and Therapeutics
- Publisher
- SAGE Publications
- Published
- 2018-02-08
- Volume
- 23
- Issue
- 2
- Pages
- 103-118
- ISSN
- 1074-2484 (ISSN-L)
- 1940-4034
- PMC
- PMC5808827
- OpenAlex
- W2794398597
- Cited by
- 31
- References
- 55
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 3 · 2022: 4 · 2020: 12 · 2019: 6 · 2018: 1
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Cardiovascular Pharmacology and Therapeutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- over-the-counter analgesics, nonsteroidal anti-inflammatory drugs, ibuprofen, naproxen, paracetamol, cardiovascular risk, PRECISION trial, celecoxib, drug safety labeling, acute pain relief
- MeSH terms
- Acetaminophen, Analgesics, Drug Labeling, Nonprescription Drugs, Heart Diseases, Humans, Ibuprofen, Kidney Diseases, Naproxen, Risk Factors, Risk Assessment, Patient Safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiorenal Safety of OTC Analgesics. https://app.cochat.ai/papers/10.1177/1074248417751070
- The paper
- White, W. B., Kloner, R. A., Angiolillo, D. J., & Davidson, M. H. (2018). Cardiorenal Safety of OTC Analgesics. Journal of Cardiovascular Pharmacology and Therapeutics. https://doi.org/10.1177/1074248417751070
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.